Application of substance for inhibiting LSECtin in preparing medicine for treating and/or preventing viral hepatitis B

A technology for viral hepatitis and hepatitis B virus, which is applied in the application field of substances used for inhibiting LSECtin in the preparation of medicines for treating and/or preventing viral hepatitis B, and can solve resistance mutation, curative effect discount, aggravation Liver disease and other problems, to achieve the effect of great social significance and economic value

Active Publication Date: 2014-09-03
INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Nucleoside analogs have fewer side effects, but the drug-resistant mutations brought about by long-term use greatly reduce the curative effect, and stopping the drug will lead to a new round of viral replication and aggravate liver disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of substance for inhibiting LSECtin in preparing medicine for treating and/or preventing viral hepatitis B
  • Application of substance for inhibiting LSECtin in preparing medicine for treating and/or preventing viral hepatitis B
  • Application of substance for inhibiting LSECtin in preparing medicine for treating and/or preventing viral hepatitis B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Embodiment 1, establish HBV infection mouse model

[0080] 1. Establishment of an animal model of HBV infection in Balb / c mice

[0081] The first group: adjust the concentration of plasmid pBS-HBV1.3 with normal saline, and then inject Balb / c mice through the tail vein within 5 sec (using the injection method of tail vein injection, the plasmid basically enters the liver), each mouse Inject 10 micrograms of plasmid, and the mass ratio of the injection to the mouse is 8%;

[0082] The second group: adjust the concentration of plasmid pAAV / HBV1.2 with normal saline, and then inject Balb / c mice through the tail vein within 5 sec. Each mouse is injected with 10 micrograms of the plasmid, and the mass ratio of the injection solution to the mouse is 8%. .

[0083] Start timing from the injection, every 24 hours is 1 day, respectively on the first day of the experiment (the first day of the experiment is 24 hours after the injection, and so on), the fourth day, the fifth day...

Embodiment 2

[0093] Example 2. After inhibiting the function of LSECtin, the elimination of viral antigens in HBV-infected mice was accelerated

[0094] The first group: adjust the concentration of plasmid pBS-HBV1.3 with normal saline, then inject Balb / c mice or Balb / c LSECtin knockout mice through the tail vein within 5sec, inject 10 micrograms of plasmid per mouse, injection solution The mass ratio to mice is 8%;

[0095] The second group: adjust the concentration of plasmid pAAV / HBV1.2 with normal saline, then inject Balb / c mice or Balb / c LSECtin knockout mice through the tail vein within 5sec, inject 10 micrograms of plasmid per mouse, and inject The mass ratio to mice is 8%;

[0096] The third group: adjust the concentration of plasmid pAAV / HBV1.2 with normal saline, then inject C57BL / 6 mice or C57BL / 6LSECtin knockout mice through the tail vein within 5sec, and inject 10 micrograms of plasmid per mouse, and the injection solution is mixed with The mass ratio of mice was 8%.

[009...

Embodiment 3

[0102] Example 3, GlcNAcβ1-2Man accelerates the clearance of viral antigens in HBV-infected mice by blocking the function of LSECtin

[0103] 1. On the first day of the experiment, adjust the concentration of plasmid pAAV / HBV1.2 with normal saline, and then inject C57BL / 6 mice through the tail vein within 5 sec. Each mouse is injected with 10 micrograms of the plasmid. The mass ratio of the injection to the mouse 8%.

[0104] 2. On the fourth day of the experiment, the mice in step 1 were divided into two groups, and the following parallel treatments were carried out respectively:

[0105] Experimental group (10 rats): each mouse was intraperitoneally injected with 0.2ml of 13μM GlcNAcβ1-2Man solution every day until the 42nd day of the experiment;

[0106] Control group (9 rats): Each mouse was injected intraperitoneally with 0.2ml of PBS buffer solution every day until the 42nd day of the experiment.

[0107] Timed from injection, on days 7, 14, 21, 28, 35, 49, 56, 63, 70,...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a substance for inhibiting LSECtin in preparing a medicine for treating and / or preventing viral hepatitis B. The invention provides application of the substance for inhibiting LSECtin in preparing a product with the following purposes: (a) treating and / or preventing viral hepatitis B; (b) promoting elimination of hepatitis B virus antigen in an infected person of hepatitis B virus; (c) treating and / or preventing infection of HBV (Hepatitis B Virus); (d) inhibiting duplication of hepatitis b viral hepatitis virus; (e) promoting increase of proportion of CD25 positive cells in liver lymphocyte; (f) promoting decrease of CD62 positive cells in liver lymphocyte; (g) promoting decrease of proportion of CD127 positive cells in liver lymphocyte; (h) promoting increase of proportion of cells which secrete interferon-gamma in liver lymphocyte. The substance disclosed by the invention has huge social meaning and economic value.

Description

technical field [0001] The present invention relates to the application of the substance for inhibiting LSECtin in the preparation of medicine for treating and / or preventing hepatitis B virus. Background technique [0002] Hepatitis B virus, called hepatitis B for short, is a common infectious disease caused by hepatitis B virus (HBV) infection. At present, there are about 2 billion HBV-infected people in the world, and my country is a high-endemic area of ​​HBV infection. Although preventive vaccines were used clinically in 1982, there are still more than 350 million chronic carriers each year, 75% of which are distributed in the Asia-Pacific region. Chronic carriers are at risk of developing liver decompensation, cirrhosis, or liver cancer, which is estimated to kill around 1 million people worldwide each year. [0003] For chronic carriers, how to completely eliminate HBV is still a very difficult problem. So far, the drugs used for the treatment of chronic hepatitis B...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7016A61P31/20A61P1/16G01N15/14G01N33/74
Inventor 唐丽贺福初王敏刘彪王晓文赵殿元
Owner INST OF RADIATION MEDICINE ACAD OF MILITARY MEDICAL SCI OF THE PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap